5 results about "Cosmeceutical" patented technology

This invention relates to a Torreya grandis seed polypeptide with antioxidant and hyaluronidase inhibitory activities, its preparation, and its application. The method includes the following steps: S1, mixing Torreya grandis seed powder and ethanol for defatting to obtain a solid phase; S2, preparing the solid phase into a solution, acidifying it, then enzymatically hydrolyzing it with pepsin, inactivating the enzyme, centrifuging to collect the liquid phase, and freeze-drying it to obtain Torreya grandis seed polypeptide powder. Compared with the prior art, this invention provides a simple, reasonable, and efficient preparation method for Torreya grandis seed polypeptide, exhibiting good activity. It also proposes the application of Torreya grandis seed polypeptide in antioxidant and hyaluronidase activity inhibition, expanding its application in the fields of cosmeceuticals and food.

The invention relates to the technical field of cosmeceuticals, in particular to a tightening essence spray. The anti-wrinkle mask is prepared from the following components in percentage by mass: 83.56% of bifidus yeast fermentation product filtrate, 6.5% of an anti-wrinkle agent A, 3.5% of an anti-wrinkle agent B, 2.5% of a preservative, 1.5% of nicotinamide, 1% of an anti-wrinkle agent C, 1% of Wailing enzyme, 0.11% of dipotassium glycyrrhizinate, 0.11% of allantoin, 0.11% of fullerene and 0.11% of hydrolyzed collagen. The anti-wrinkle agent A contains arginine / lysine polypeptide, and the molecular weight of the anti-wrinkle agent A is 1t; the 500Da oligopeptide chain can directly penetrate through the stratum corneum, and is competitively combined with the SNAP-25 protein to block the transmission of neuromuscular signals. The anti-wrinkle agent B contains acetyl hexapeptide-8, and forms a'nerve blocking-muscle relaxing 'closed loop with the anti-wrinkle agent A by inhibiting a calcium ion channel and reducing the depth of dynamic lines, and the effect is remarkable. The nicotinamide in the invention blocks melanosome transfer, activates an AMPK pathway to promote autophagy flow, and accelerates the degradation of generated melanin. The dipotassium glycyrrhizinate inhibits COX-2 inflammatory enzyme, reduces the level of PGE2 inflammatory factors induced by ultraviolet rays, and blocks inflammatory chromaticity.

The present invention relates to heparan sulfate sugar mimetic compounds as heparan sulfate mimetics, and the use of these compounds as medicaments, cosmeceuticals and as molecular probes. The invention also relates to intermediate compounds useful in the preparation of various sugar mimetic compounds. The invention is particularly suitable for treating or preventing diseases such as cancer, inflammation, diabetic nephropathy, neurodegenerative diseases, for bone healing or wound healing, for cosmeceutical use, and as molecular probes comprising imaging agents.

The claimed solution relates to pharmaceuticals, cosmeceuticals, medicine and veterinary medicine and can be used for producing an effective and safe analgesic for the treatment of pain of different origins, thereby providing relief for acute and chronic pain. The solution is directed toward the development of radically new analgesics of endogenous origin capable of rivaling opiates and opioids in a variety of indices. The essence of the solution consists in a technology for the creation of an analgesic substance that is a chelate complex of general formula CTS-M2+, where CTS is a molecule of a cardiotonic steroid, and М2+ is any doubly charged inorganic cation. In a specific embodiment, the substance is a calcium chelate complex of a molecule of ouabain. Proposed are methods for administering a pharmaceutical composition based on the claimed analgesic substance, which is provided in an injectable form or in the form of a cream, ointment, gel or the like.

A composition of rhPDGF-BB for the regeneration, rejuvenation, strengthening, comfort or aesthetic usefulness of soft tissue in the field of cosmetics and cosmeceuticals, comprising rhPDGF-BB combined with a carrier selected from the group consisting of different types of collagen, gelatin, alginates, polysaccharides, glycosaminoglycans, fibrin, hyaluronic acid and derivatives or combinations thereof, wherein damage to skin or soft tissue is treated by application of the disclosed composition.